Comment on “Tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients”

Julia E. Geddings; Nigel Mackman

doi:10.1160/TH13-07-0599

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2014; 111(01): 180-181
DOI: 10.1160/TH13-07-0599

Author Correspondence

Schattauer GmbH

Comment on “Tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients”

Julia E. Geddings

¹Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA

,

Nigel Mackman

¹Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA

²Division of Hematology/Oncology, Thrombosis and Hemostasis Program, UNC McAllister Heart Institute, University of North Carolina, Chapel Hill, North Carolina, USA

³Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA

References
1 Hernandez C, Orbe J, Roncal C. et al. Tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients. Thromb Haemost 2013; 110: 598-608.
2 Gyorgy B, Szabo TG, Pasztoi M. et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci 2011; 68: 2667-2688.
3 Lacroix R, Robert S, Poncelet P. et al. Overcoming limitations of microparticle measurement by flow cytometry. Semin Thromb Hemost 2010; 36: 807-818.
4 Lacroix R, Robert S, Poncelet P. et al. Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 2010; 8: 2571-2574.
5 van der Pol E, Coumans F, Varga Z. et al. Innovation in detection of microparticles and ex-osomes. J Thromb Haemost 2013; 11 (Suppl. 01) 36-45.
6 Basavaraj MG, Olsen JO, Osterud B. et al. Differential ability of tissue factor antibody clones on detection of tissue factor in blood cells and micro-particles. Thromb Res 2012; 130: 538-546.
7 van Doormaal F, Kleinjan A, Berckmans RJ. et al. Coagulation activation and microparticle-associ-ated coagulant activity in cancer patients. An exploratory prospective study. Thromb Haemost 2012; 108: 160-165.
8 Kleinjan A, Boing AN, Sturk A. et al. Micropar-ticles in vascular disorders: how tissue factor-exposing vesicles contribute to pathology and physiology. Thromb Res 2012; 130 (Suppl. 01) S71-73.
9 Lee RD, Barcel DA, Williams JC. et al. Pre-analyti- cal and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity. Thromb Res 2012; 129: 80-85.
10 Bogdanov VY, Cimmino G, Tardos JG. et al. Assessment of plasma tissue factor activity in patients presenting with coronary artery disease: limitations of a commercial assay. J Thromb Haemost 2009; 7: 894-897.
11 Parhami-Seren B, Butenas S, Krudysz-Amblo J. et al. Immunologic quantitation of tissue factors. J Thromb Haemost 2006; 4: 1747-1755.
12 Haubold K, Rink M, Spath B. et al. Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thromb Haemost 2009; 101: 1147-1155.
13 Hull RD, Pineo GF, Brant RF. et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119: 1062-1072.
14 Lee AY, Levine MN, Baker RI. et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.